X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs SUN PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. SUN PHARMA WOCKHARDT LTD./
SUN PHARMA
 
P/E (TTM) x -15.2 23.6 - View Chart
P/BV x 2.5 3.4 72.5% View Chart
Dividend Yield % 1.3 0.7 198.0%  

Financials

 WOCKHARDT LTD.   SUN PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
SUN PHARMA
Mar-17
WOCKHARDT LTD./
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,129842 134.1%   
Low Rs627572 109.5%   
Sales per share (Unadj.) Rs363.1131.6 275.9%  
Earnings per share (Unadj.) Rs-20.432.7 -62.5%  
Cash flow per share (Unadj.) Rs-7.038.0 -18.4%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.10.5 230.1%  
Book value per share (Unadj.) Rs301.8152.7 197.6%  
Shares outstanding (eoy) m110.552,399.26 4.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.45.4 45.0%   
Avg P/E ratio x-42.921.6 -198.6%  
P/CF ratio (eoy) x-125.918.6 -675.9%  
Price / Book Value ratio x2.94.6 62.8%  
Dividend payout %-48.910.7 -457.0%   
Avg Mkt Cap Rs m97,0631,696,877 5.7%   
No. of employees `0006.817.5 38.6%   
Total wages/salary Rs m9,66549,023 19.7%   
Avg. sales/employee Rs Th5,931.818,028.3 32.9%   
Avg. wages/employee Rs Th1,428.12,798.8 51.0%   
Avg. net profit/employee Rs Th-334.04,479.5 -7.5%   
INCOME DATA
Net Sales Rs m40,146315,784 12.7%  
Other income Rs m1,1436,232 18.3%   
Total revenues Rs m41,289322,016 12.8%   
Gross profit Rs m128100,893 0.1%  
Depreciation Rs m1,48912,648 11.8%   
Interest Rs m2,2533,998 56.3%   
Profit before tax Rs m-2,47290,479 -2.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-21112,116 -1.7%   
Profit after tax Rs m-2,26078,462 -2.9%  
Gross profit margin %0.331.9 1.0%  
Effective tax rate %8.513.4 63.8%   
Net profit margin %-5.624.8 -22.7%  
BALANCE SHEET DATA
Current assets Rs m46,160329,537 14.0%   
Current liabilities Rs m19,258178,870 10.8%   
Net working cap to sales %67.047.7 140.4%  
Current ratio x2.41.8 130.1%  
Inventory Days Days10179 127.5%  
Debtors Days Days9483 113.0%  
Net fixed assets Rs m40,165204,766 19.6%   
Share capital Rs m5532,399 23.0%   
"Free" reserves Rs m32,814363,997 9.0%   
Net worth Rs m33,367366,397 9.1%   
Long term debt Rs m31,90314,361 222.2%   
Total assets Rs m89,687614,102 14.6%  
Interest coverage x-0.123.6 -0.4%   
Debt to equity ratio x1.00 2,439.4%  
Sales to assets ratio x0.40.5 87.0%   
Return on assets %013.4 -0.1%  
Return on equity %-6.821.4 -31.6%  
Return on capital %-0.324.8 -1.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,12144,118 20.7%   
Fx outflow Rs m2,13324,484 8.7%   
Net fx Rs m6,98819,634 35.6%   
CASH FLOW
From Operations Rs m-2,69570,822 -3.8%  
From Investments Rs m-6,863-42,216 16.3%  
From Financial Activity Rs m12,545-22,854 -54.9%  
Net Cashflow Rs m3,0106,107 49.3%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 5.1 44.8%  
FIIs % 7.7 23.0 33.5%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 8.3 185.5%  
Shareholders   67,757 133,026 50.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 21, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS